Current Report Filing (8-k)
May 09 2019 - 8:20AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Act of 1934
Date of Report (Date of earliest event reported): May 9, 2019
MAGENTA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-38541
|
|
81-0724163
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification Number)
|
|
|
|
|
|
100 Technology Square
Cambridge, Massachusetts
|
|
|
|
02139
|
(Address of principal executive offices)
|
|
|
|
(Zip Code)
|
Registrants telephone number, including area code: (857)
242-0170
Check the
appropriate box below if the
Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to
Rule 14a-12
under the Exchange Act
(17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to
Rule 14d-2(b) under
the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to
Rule 13e-4(c) under
the Exchange Act (17 CFR
240.13d-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities
registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock, $0.001 Par Value
|
|
MGTA
|
|
The Nasdaq Global Market
|
Item 2.02
|
Results of Operations and Financial Condition.
|
On May 9, 2019, Magenta Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2019. The full text of the press
release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on
Form 8-K.
The information in this
Form 8-K
(including Exhibit 99.1) shall not be deemed filed for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of
1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01
|
Financial Statements and Exhibits.
|
The following exhibit relating to Item 2.02 shall be deemed furnished, and not filed:
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
MAGENTA THERAPEUTICS, INC.
|
|
|
|
|
|
|
|
|
Date:
|
|
May 9, 2019
|
|
|
|
|
By:
|
|
/s/ Jason Gardner
|
|
|
|
|
Title:
|
|
President and Chief Executive Officer
|
3
Magenta Therapeutics (NASDAQ:MGTA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Magenta Therapeutics (NASDAQ:MGTA)
Historical Stock Chart
From Sep 2023 to Sep 2024